IAA10 Antibody

What is IAA10 and what is its function in plants?

IAA10 is an Aux/IAA protein that acts as a transcriptional repressor in auxin signaling pathways. It belongs to a family of short-lived transcription factors that function as repressors of early auxin response genes at low auxin concentrations. In Arabidopsis thaliana, IAA10 plays a significant role in regulating seedling development processes including hypocotyl elongation, apical hook maintenance, and cotyledon expansion . Like other Aux/IAA proteins, IAA10 contains a domain II (DII) degron that mediates interaction with the TIR1/AFB auxin receptors and an SBC (substrate binding for Cullin3) domain that mediates interaction with BTB/POZ-MATH (BPM) proteins .

How should IAA10 antibodies be stored and handled?

IAA10 antibodies should typically be stored according to manufacturer specifications. For lyophilized antibodies:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles

• Products are typically shipped at 4°C and should be stored immediately at the recommended temperature upon receipt

• For working solutions, aliquot to minimize freeze-thaw cycles

• Follow manufacturer's recommendations for reconstitution procedures

What are the standard applications for IAA10 antibodies?

IAA10 antibodies are primarily used in plant molecular biology research for:

• Western blotting to detect IAA10 protein expression levels

• Immunoprecipitation (IP) to study protein-protein interactions

• Immunofluorescence to study subcellular localization

• Chromatin immunoprecipitation (ChIP) to study DNA-protein interactions

Research has demonstrated that IAA10 protein accumulates in both the nucleus and cytoplasm of plant cells, and this localization pattern can be detected using immunofluorescence techniques with specific IAA10 antibodies .

How can I validate the specificity of an IAA10 antibody?

For rigorous validation of IAA10 antibodies, researchers should implement multiple strategies based on the "five pillars" of antibody characterization :

• Genetic strategies: Use IAA10 knockout/knockdown lines as negative controls

• Orthogonal strategies: Compare antibody results with independent methods (e.g., GFP-tagged IAA10 expression)

• Multiple antibody strategies: Compare results using different antibodies targeting different epitopes of IAA10

• Recombinant expression: Use overexpression systems to confirm signal amplification

• Immunocapture MS strategies: Validate using mass spectrometry to identify captured proteins

Proper validation should document:

• The antibody binds to IAA10 protein specifically

• The antibody binds to IAA10 when in complex mixtures (e.g., whole cell lysate)

• The antibody does not bind to proteins other than IAA10

• The antibody performs as expected in specific experimental conditions

What control samples should I use when working with IAA10 antibodies?

Recent studies have used pIAA10:IAA10-GFP transgenic lines crossed with mutant backgrounds (e.g., bpm1,4,5) as excellent controls for antibody validation .

How can I detect low abundance IAA10 protein in plant tissues?

IAA10 is a short-lived protein that can be difficult to detect under normal conditions. Research strategies to enhance detection include:

• Auxin treatment: Treating samples with auxin can enhance IAA10 transcription, making protein more detectable. In studies with pIAA10:IAA10-GFP lines, IAA10-GFP remained faint in wild-type backgrounds but became detectable in bpm1,4,5 mutant backgrounds following IAA treatment .

• Proteasome inhibitors: Since IAA10 undergoes ubiquitin-mediated degradation, treating samples with proteasome inhibitors (e.g., MG132) can increase protein accumulation.

• Enrichment techniques:

  • Immunoprecipitation before Western blotting

  • Cellular fractionation to concentrate nuclear proteins

  • Use of more sensitive detection systems (e.g., chemiluminescence)

• Sample optimization: Optimize extraction buffers with appropriate protease inhibitors and reducing agents to prevent degradation during processing.

How do BPM proteins interact with IAA10 and how can I study this interaction?

BPM (BTB/POZ-MATH) proteins are substrate adaptors for CUL3-based E3 ubiquitin ligases that interact with and regulate IAA10 stability. To study this interaction:

• Yeast two-hybrid (Y2H) assays: Research has shown that BPM1, BPM3, and BPM4 strongly interact with IAA10, while BPM2 interacts weakly. BPM5 and BPM6 don't demonstrate interaction in Y2H systems .

• Bimolecular Fluorescence Complementation (BiFC): This technique confirms in vivo interaction in plant cells. BPM1-IAA10 interaction has been confirmed in N. benthamiana leaves using BiFC .

• Co-immunoprecipitation (Co-IP): Co-IP assays in Arabidopsis mesophyll protoplasts have verified the physical interaction between BPM1 and IAA10 .

• Domain mapping: Studies have identified that BPM1 interacts with the SBC domain of IAA10. Mutating the SBC domain (IAA10-SBC mutation) disrupts this interaction .

• Ubiquitylation assays: Co-expression of BPM1 with IAA10 in protoplasts results in increased ubiquitylation of IAA10, which can be detected using GFP-Trap beads to precipitate IAA10-GFP followed by ubiquitin immunoblotting .

How can I determine if my antibody recognizes specific domains or modifications of IAA10?

To characterize domain-specific recognition:

• Epitope mapping: Use truncated recombinant versions of IAA10 expressing different domains to determine which region the antibody recognizes.

• Domain mutants: Test antibody against IAA10 variants with mutations in specific domains (e.g., DII degron mutants or SBC domain mutants). Research has shown that IAA10 has different functional domains that can be experimentally mutated:

  • DII degron (GWPSL) mediates interaction with TIR1/AFB

  • SBC domain (LSAAA) mediates interaction with BPM proteins

• Post-translational modification analysis: To determine if your antibody recognizes specific modifications:

  • Compare detection in samples treated with phosphatases, deubiquitinases, or other enzymes

  • Use phospho-specific or ubiquitin-specific antibodies in parallel

  • Compare samples with and without auxin treatment, which affects IAA10 ubiquitylation

What are optimal protocols for detecting IAA10 using Western blotting?

Based on research practices with IAA10 and related proteins:

• Sample preparation:

  • Extract proteins in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% NP-40, 1 mM DTT

  • Include protease inhibitor cocktail and 50 μM MG132 if studying protein stability

  • For membrane proteins, include 1% Triton X-100

• Gel electrophoresis:

  • Use 10-12% SDS-PAGE for optimal separation

  • IAA10 has a predicted molecular weight of approximately 30 kDa

• Transfer and detection:

  • PVDF membranes typically work better than nitrocellulose for plant proteins

  • Block with 5% non-fat milk or 3% BSA in TBST

  • Incubate with IAA10 primary antibody at 1:1000 to 1:2000 dilution (optimize as needed)

  • Use enhanced chemiluminescence detection

• Controls:

  • Include IAA10 overexpression and knockout samples

  • For degradation studies, include samples treated with cycloheximide (CHX), a protein synthesis inhibitor

How can I study IAA10 degradation dynamics?

IAA10 is a short-lived protein regulated by both TIR1/AFB-mediated and BPM-mediated degradation pathways. To study degradation dynamics:

• Cycloheximide (CHX) chase assays:

  • Treat samples with CHX to inhibit new protein synthesis

  • Collect samples at various time points (0, 15, 30, 60, 120 min)

  • Perform Western blotting to track IAA10 degradation rate

  • Research has shown that IAA10 degradation occurs more rapidly when BPM1 is co-expressed

• Proteasome inhibition:

  • Treat samples with MG132 to inhibit proteasomal degradation

  • Compare protein levels with and without inhibitor treatment

• Ubiquitylation assays:

  • Co-express IAA10-GFP with or without BPM1

  • Immunoprecipitate IAA10-GFP using GFP-Trap beads

  • Probe with anti-ubiquitin antibodies to detect ubiquitylation levels

  • Studies have shown that co-expression with BPM1 leads to higher ubiquitylation levels on IAA10-GFP

How can I optimize immunofluorescence protocols for detecting endogenous IAA10?

For successful immunofluorescence detection of IAA10:

• Fixation and permeabilization:

  • Fix tissues in 4% paraformaldehyde for 20-30 minutes

  • Permeabilize with 0.1-0.2% Triton X-100

  • For detection in specific cell types, optimize fixation time

• Antigen retrieval:

  • May be necessary for formalin-fixed tissues

  • Citrate buffer (pH 6.0) at 95°C for 10-20 minutes can improve epitope accessibility

• Antibody optimization:

  • Test a range of primary antibody dilutions (1:100 to 1:500)

  • Extended incubation (overnight at 4°C) often improves signal

  • NeuroMab protocols suggest using transfected cells expressing the antigen as positive controls for antibody testing

• Signal enhancement:

  • Use tyramide signal amplification for low abundance proteins

  • Consider using highly cross-adsorbed secondary antibodies to reduce background

• Controls:

  • Include IAA10 knockout tissue as negative control

  • Use pIAA10:IAA10-GFP transgenic lines as positive controls and for co-localization studies

  • Studies have shown that IAA10 protein accumulates in both the nucleus and cytoplasm

How can machine learning and active learning be applied to improve IAA10 antibody development?

Recent advances in machine learning offer promising approaches for antibody research:

• Library-on-library screening optimization:

  • Machine learning models can predict antibody-antigen binding by analyzing many-to-many relationships

  • Active learning strategies can reduce experimental costs by starting with small labeled subsets and iteratively expanding

  • Research has shown that active learning can reduce the number of required antigen mutant variants by up to 35%

• Epitope prediction:

  • Computational models can predict likely epitopes on IAA10

  • These predictions can guide design of more specific antibodies

  • Active learning approaches have been shown to speed up the learning process by 28 steps compared to random baseline methods

• Specificity optimization:

  • Machine learning can identify potential cross-reactivity with similar proteins

  • This information can guide antibody design to enhance specificity

What are the emerging techniques for studying IAA10 protein interactions with higher sensitivity?

Recent methodological advances offer increased sensitivity for studying IAA10:

• Proximity labeling techniques:

  • BioID or TurboID fused to IAA10 can identify proximal proteins in vivo

  • APEX2 provides spatial and temporal resolution of interactions

• Single-molecule imaging:

  • Super-resolution microscopy (STORM, PALM) can visualize IAA10 distribution at nanometer resolution

  • Single-molecule tracking can reveal IAA10 dynamics in living cells

• Mass spectrometry-based approaches:

  • Cross-linking mass spectrometry (XL-MS) can map interaction interfaces

  • Parallel reaction monitoring (PRM) can quantify IAA10 with high sensitivity

  • The YCharOS initiative has developed consensus protocols for antibody characterization using multiple techniques including mass spectrometry

• Recombinant antibody technologies:

  • Recent workshops (March 2024) have demonstrated that recombinant antibodies are more effective than polyclonal antibodies and far more reproducible

  • Recombinant antibody sequences can be made publicly available to enhance reproducibility